Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan McCone

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|June 13, 2002
Induction of IL-1Ra in resistant and responsive hepatitis C patients following treatment with IFN-con1Scott J Cotler, Teresa Craft, Mary Ferris, et al.
The New England Journal of Medicine|April 1, 2011
Boceprevir for untreated chronic HCV genotype 1 infectionFred Poordad, Jonathan McCone, Bruce R Bacon, et al.
Hepatology (Baltimore, Md.)|September 27, 2007
Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1Ira M Jacobson, Robert S Brown, Jonathan McCone, et al.
Gastroenterology|August 21, 2010
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rateMark S Sulkowski, Mitchell L Shiffman, Nezam H Afdhal, et al.
Lancet (London, England)|August 10, 2010
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trialPaul Y Kwo, Eric J Lawitz, Jonathan McCone, et al.
Hepatology (Baltimore, Md.)|April 14, 2011
Racial differences in hepatitis C treatment eligibilityMichael T Melia, Andrew J Muir, Jonathan McCone, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 15, 2013
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trialsMichael P Manns, Jonathan McCone, Mitchell N Davis, et al.
Journal of Hepatology|December 24, 2013
Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null responseJohn M Vierling, Mitchell Davis, Steven Flamm, et al.
The New England Journal of Medicine|July 24, 2009
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infectionJohn G McHutchison, Eric J Lawitz, Mitchell L Shiffman, et al.
Antiviral Therapy|February 15, 2013
Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trialRobert A Ogert, John A Howe, John M Vierling, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|June 13, 2002
Induction of IL-1Ra in resistant and responsive hepatitis C patients following treatment with IFN-con1Scott J Cotler, Teresa Craft, Mary Ferris, et al.
The New England Journal of Medicine|April 1, 2011
Boceprevir for untreated chronic HCV genotype 1 infectionFred Poordad, Jonathan McCone, Bruce R Bacon, et al.
Hepatology (Baltimore, Md.)|September 27, 2007
Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1Ira M Jacobson, Robert S Brown, Jonathan McCone, et al.
Gastroenterology|August 21, 2010
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rateMark S Sulkowski, Mitchell L Shiffman, Nezam H Afdhal, et al.
Lancet (London, England)|August 10, 2010
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trialPaul Y Kwo, Eric J Lawitz, Jonathan McCone, et al.
Hepatology (Baltimore, Md.)|April 14, 2011
Racial differences in hepatitis C treatment eligibilityMichael T Melia, Andrew J Muir, Jonathan McCone, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 15, 2013
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trialsMichael P Manns, Jonathan McCone, Mitchell N Davis, et al.
Journal of Hepatology|December 24, 2013
Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null responseJohn M Vierling, Mitchell Davis, Steven Flamm, et al.
The New England Journal of Medicine|July 24, 2009
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infectionJohn G McHutchison, Eric J Lawitz, Mitchell L Shiffman, et al.
Antiviral Therapy|February 15, 2013
Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trialRobert A Ogert, John A Howe, John M Vierling, et al.
Pageof 2